The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Preliminary promise for venetoclax and 3+7 in untreated AML
The results of a phase 1 trial (NCT03709758) of escalating doses of venetoclax with daunorubicin/cytarabine (7+3) induction and high dose cytarabine consolidation in untreated adults acute myeloid leukemia (AML) were presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Here Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results, which show promise.
